Filings

4 documents · 4 matches

1. FHTX Foghorn Therapeutics Inc. 8-K 2026-01-12

   material weaknesses in the Company’s internal control over financial reporting (whether or not remediated) and no change in the Company
   1 match in this document Show context Copy citation

2. FHTX Foghorn Therapeutics Inc. 10-Q 2026-08-06

   material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect
   1 match in this document Show context Copy citation

3. FHTX Foghorn Therapeutics Inc. 424B4 2020-10-23

   material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability
   1 match in this document Show context Copy citation

4. FHTX Foghorn Therapeutics Inc. S-1/A 2020-10-22

   material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability
   1 match in this document Show context Copy citation